Abstract: The present invention relates to methods of identifying Cannabis sativa plants comprising quantitative trait loci (QTLs) associated with a high-varin trait, and to Cannabis sativa plants comprising these QTLs. The invention also relates to plants with increased levels of varin content which are identified by the methods of the invention. The invention further relates to marker assisted selection and marker assisted breeding methods for obtaining plants having a high-varin trait, as well as to methods of producing Cannabis sativa plants with increased levels of varins and plants produced by these methods.

Abstract: A container having a barrier layer is provided. The container may be of thermoplastic and the barrier may inhibit materials from leaching from the thermoplastic material or from extraction of compounds from medicants by the thermoplastic. A process is also described that allows for molding thin barrier layers as container lines and for forming thermoplastic containers with barrier liners.

Abstract: A container having a barrier layer is provided. The container may be of thermoplastic and the barrier may inhibit materials from leaching from the thermoplastic material or from extraction of compounds from medicants by the thermoplastic. A process is also described that allows for molding thin barrier layers as container lines and for forming thermoplastic containers with barrier liners.

Abstract: A pre-filled syringe having containing therein at least one therapeutic is provided. The syringe contains a silicone free barrel and an elastomeric syringe stopper that is covered with an expanded polytetrafluoroethylene barrier layer. The presence of a barrier layer that is at least partially porous on the outside of the syringe stopper improves the seal between the stopper and syringe barrel and minimizes the sliding force. In some embodiments, the barrel is formed of a glass material such as a borosilicate glass, that is free of silicone or other lubricants.

Abstract: A pre-filled syringe having containing therein at least one therapeutic is provided. The syringe contains a silicone free barrel and an elastomeric syringe stopper that is covered with an expanded polytetrafluoroethylene barrier layer. The presence of a barrier layer that is at least partially porous on the outside of the syringe stopper improves the seal between the stopper and syringe barrel and minimizes the sliding force. In some embodiments, the barrel is formed of a glass material such as a borosilicate glass, that is free of silicone or other lubricants.

Abstract: A container having a barrier layer is provided. The container may be of thermoplastic and the barrier may inhibit materials from leaching from the thermoplastic material or from extraction of compounds from medicants by the thermoplastic. A process is also described that allows for molding thin barrier layers as container lines and for forming thermoplastic containers with barrier liners.

Abstract: An ophthalmological device (1) for processing eye tissue includes a projection optical unit for focused projection of a laser beam (L) into the eye tissue, and a scanner system upstream of the projection optical unit for beam-deflecting scanning of the eye tissue with the laser beam (L) in a scanning movement (s') performed over a scanning angle along a scanning line(s). The ophthalmological device includes at least one optical element upstream of the projection optical unit, the optical element configured to generate a divergence—dependent on the scanning angle—of the laser beam (L), the scanning line(s) tilted in a plane running through the optical axis of the projection optical unit and the scanning line(s). Tilting of the scanning line(s)displaces—dependent on the scanning angle—the focus of the laser pulses projected into the eye tissue without vertical displacement of the projection optical unit.

Abstract: An ophthalmological device (1) for processing eye tissue includes a projection optical unit for focused projection of a laser beam (L) into the eye tissue, and a scanner system upstream of the projection optical unit for beam-deflecting scanning of the eye tissue with the laser beam (L) in a scanning movement (s?) performed over a scanning angle along a scanning line(s). The ophthalmological device includes at least one optical element upstream of the projection optical unit, the optical element configured to generate a divergence—dependent on the scanning angle—of the laser beam (L), the scanning line(s) tilted in a plane running through the optical axis of the projection optical unit and the scanning line(s). Tilting of the scanning line(s) displaces—dependent on the scanning angle—the focus of the laser pulses projected into the eye tissue without vertical displacement of the projection optical unit.

Abstract: A bio-molecular contrast agent (BMCA) is introduced into a biological organism such that the agent binds or reacts with target tissue within that organism. The BMCA is also signal-giving, and signal reactive, capable of being inactivated by delivery of energy thereto. By monitoring the decrease in signal strength of the BMCA, the actual dosage delivered to the target can be determined and monitored. The decrease in BMCA signal strength can also be correlated to the level of destruction of the target, allowing for determination of therapy success.

Abstract: A laser cutting system and method are provided. The system (10) includes an electronically controllable robot (12) for bringing a laser cutting head (22) to prescribable reference positions with respect to a workpiece (24), a programmable control device (18), provided with a memory, for controlling the robot (12) with respect to reference position coordinates stored in the memory, and a distance correcting device (26) for correcting the distance of the laser cutting head (22) from the workpiece after the laser cutting head (22) has been brought to the reference position defined by the reference position coordinates. To ensure a prescribed quality standard during the laser cutting, certain tolerances on the workpiece (24) must be maintained.

Abstract: A method is proposed for carrying out quality control on an analytical process which belongs to a group of related analytical processes that can be executed in at least one analytical device and includes a respective chain of sub-processes. The method includes fundamental chemical and/or physical underlying sub-processes being stored for the group in a first database. Further, at least one section of the chain of the analytical process is emulated by the specification of one of the underlying sub-processes for each sub-process in a section of the chain, using at least one control parameter and at least one corresponding threshold value. Finally, measured values are determined for the control parameters for at least one run of the analytical process and the measured values are compared with the corresponding threshold values for the quality control procedure.

Abstract: A medical imaging system with a scanning subsystem configured to acquire imaging data is provided. Also provided is a controller configured to selectively control power to at least one component of the system based on a mode of operation of the scanning subsystem.

Abstract: A medical imaging system is provided that includes a plurality of circuit boards configured to be tested using boundary scan test vectors. A controller of the medical imaging system is configured to test the plurality of circuit boards. The controller is further configured to access test profiles to perform boundary scan tests on the plurality of circuit boards based on the test profiles.

Abstract: A beamformer for an ultrasound system and a method for developing a beamformer are provided. The beamformer includes an RF interface configured to be connected to receiver boards that are connected to a probe. The method includes providing receiver boards, wherein each of the receiver boards is capable of conveying a common number of channels per board and has substantially similar circuit components and layouts. The method also includes selecting a number of channels per probe to be conveyed in parallel between a probe and the receiver boards, wherein the channels per probe is an integer multiple of the channels per board. The method further includes determining a combination of the receiver boards to use in the beamformer based on the number of channels per probe, wherein the receiver boards are capable of being used in at least first and second different combinations that support first and second different numbers of channels per probe.

Abstract: A method is proposed for carrying out quality control on an analytical process which belongs to a group of related analytical processes that can be executed in at least one analytical device and includes a respective chain of sub-processes. The method includes fundamental chemical and/or physical underlying sub-processes being stored for the group in a first database. Further, at least one section of the chain of the analytical process is emulated by the specification of one of the underlying sub-processes for each sub-process in a section of the chain, using at least one control parameter and at least one corresponding threshold value. Finally, measured values are determined for the control parameters for at least one run of the analytical process and the measured values are compared with the corresponding threshold values for the quality control procedure.

Abstract: A bio-molecular contrast agent (BMCA) is introduced into a biological organism such that the agent binds or reacts with target tissue within that organism. The BMCA is also signal-giving, allowing control of particle beam therapy by tracking the signal given by BMCA. The BMCA gives multiple signals which interact with different tissue elements in different ways. The variance in these signals is utilized to determine the constituency of the tissue either before and/or during therapy.

Abstract: Bio-molecular contrast agents (BMCA) can be used for optimizing radiation dosage, energy and/ or duration in order to achieve on-line, real-time therapy optimization. The BMCA signals during treatment are compared with expected values to determine what, if any, therapy optimization is needed.

Abstract: A bio-molecular contrast agent (BMCA) is introduced into a biological organism such that the agent binds or reacts with target tissue within that organism. The BMCA is also signal-giving, and signal reactive, capable of being inactivated by delivery of energy thereto. By monitoring the decrease in signal strength of the BMCA, the actual dosage delivered to the target can be determined and monitored. The decrease in BMCA signal strength can also be correlated to the level of destruction of the target, allowing for determination of therapy success.

Abstract: A magnetic stimulation apparatus for triggering action potentials, particularly in more deeply disposed, neuro-muscular tissue of a patient as well, has at least one stimulation coil that has terminals connected to the output of a current-generating unit offers greater degrees of freedom in the selection of the current pulse shapes because the current-generating unit provides current pulses generated in non-resonant fashion for the stimulation coil.

Abstract: A new and distinct Cannabis plant named ‘Pure Red 3’ is characterized by its unique pungent strawberry aroma that is distinct and clearly recognizable. ‘Pure Red 3’ has a high flower to biomass ratio and a relatively short flowering time compared with other commercial varieties known to the inventors.